<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pneumonia in children: Inpatient treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pneumonia in children: Inpatient treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pneumonia in children: Inpatient treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J Barson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. CAP is a common and potentially serious illness with considerable morbidity.
        </p>
        <p>
         The inpatient treatment of CAP and hospital-acquired pneumonia in children will be reviewed here. Our recommendations are largely consistent with practice guidelines provided by
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fcid%2Farticle%2F53%2F7%2Fe25%2F424286&amp;token=i%2BIJbZ3566jvLjqylaYc8D23O%2Fk2m8qRPrU4n4GJeOmZSxbKawUFLkPG3kI4aee0c7jLWp%2FDXr8yBnf%2FRNPROA%3D%3D&amp;TOPIC_ID=6054" target="_blank">
          the Pediatric Infectious Diseases Society/Infectious Diseases Society of America
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fthorax.bmj.com%2Fcontent%2F66%2FSuppl_2%2Fii1&amp;token=V0mX5sOwAkj5yWnOxs1IkqKBAcUVIgOr7RJ9%2Fvmb77Z9CYm%2F3xv9Cm%2FMIm%2BaYw2d1P%2B7GUQU%2FSdMP29intg5Vw%3D%3D&amp;TOPIC_ID=6054" target="_blank">
          British Thoracic Society
         </a>
         [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p>
         The outpatient treatment of CAP; the epidemiology, etiology, clinical features, and diagnosis of CAP in children; and the management of coronavirus disease 2019-related pneumonia are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">
          "Pneumonia in children: Epidemiology, pathogenesis, and etiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">
          "COVID-19: Management in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HOSPITALIZATION
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to hospitalize a child with community-acquired pneumonia (CAP) is individualized based upon age, underlying medical problems, and clinical factors including severity of illness  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. Hospitalization generally is warranted for infants younger than three to six months of age, unless a viral etiology or
         <em>
          Chlamydia
         </em>
         <em>
          trachomatis
         </em>
         is suspected and they are not hypoxemic and relatively asymptomatic. Hospitalization is also warranted for a child of any age whose caregivers cannot provide appropriate care and assure compliance with the management plan. Additional indications for hospitalization include [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoxemia (peripheral capillary oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] &lt;90 percent in room air at sea level)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dehydration, or inability to maintain hydration orally; inability to feed in an infant
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe respiratory distress: Respiratory rate &gt;70 breaths/minute for infants &lt;12 months of age and &gt;50 breaths per minute for older children; retractions; nasal flaring; difficulty breathing; apnea; grunting
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Toxic appearance (more common in bacterial pneumonia and may suggest a more severe course) [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying conditions that may predispose to a more serious course of pneumonia (eg, cardiopulmonary disease, genetic syndromes, neurocognitive disorders), may be worsened by pneumonia (eg, metabolic disorder) or may adversely affect response to treatment (eg, immunocompromised host)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications (eg, effusion/empyema, necrotizing process, abscess)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspicion or confirmation that CAP is due to a pathogen with increased virulence, such as
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         or group A
         <em>
          Streptococcus
         </em>
         (GAS)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure of outpatient therapy (worsening or no response in 48 to 72 hours)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Indications for intensive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to treat a child with pneumonia in an intensive care setting is individualized, based upon clinical, laboratory, and radiologic findings. Treatment in an intensive care setting generally is warranted for children who manifest [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The need for ventilatory support beyond that which can be provided outside the intensive care unit (ICU; eg, mechanical ventilation, noninvasive positive pressure ventilation, failure to maintain SpO
         <sub>
          2
         </sub>
         &gt;92 percent in fraction of inspired oxygen [FiO
         <sub>
          2
         </sub>
         ] &gt;0.5)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs of impending respiratory failure (lethargy, increasing work of breathing, and/or exhaustion with or without hypercarbia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent apnea or slow irregular respirations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular compromise with progressive tachycardia and/or hypotension that requires or is refractory to fluid management
        </p>
        <p>
        </p>
        <p>
         Care in the ICU also may be warranted for children with two or more of the following [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory rate &gt;70 breaths/minute for infants &lt;12 months of age and &gt;50 breaths/minute for older children
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apnea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased work of breathing (retractions, dyspnea, nasal flaring, grunting)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial pressure of oxygen in arterial blood (PaO
         <sub>
          2
         </sub>
         ):FiO
         <sub>
          2
         </sub>
         ratio &lt;250
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multilobar infiltrates
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleural effusion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid condition (eg, sickle cell disease, immune deficiency, immunosuppression)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained metabolic acidosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pediatric Early Warning Score &gt;6 [
         <a href="#rid5">
          5
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAP can be caused by a variety of microbial agents requiring a variety of infection-control measures [
         <a href="#rid6">
          6
         </a>
         ]. If possible, rapid diagnostic tests should be performed at the time of admission to facilitate decisions regarding appropriate precautions. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Approach to microbiologic testing'
         </a>
         .)
        </p>
        <p>
         Hand washing is the single most important procedure to prevent the spread of infection. Guidelines for hand hygiene in health care settings can be accessed through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fhandhygiene%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLIWTepL4%2FB4s96i92A621hyifv2FZ2wVzfvDZZenqcyb&amp;TOPIC_ID=6054" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         .
        </p>
        <p>
         Additional infection control measures depend upon the likely pathogen(s), as follows [
         <a href="#rid6">
          6,7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory syncytial, parainfluenza, and human metapneumovirus – Gown and gloves (ie, contact precautions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza and rhinoviruses, GAS (for the first 24 hours of treatment), methicillin-susceptible
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         ,
         <em>
          Bordetella
         </em>
         <em>
          pertussis
         </em>
         (until patient has received five days of effective therapy), and
         <em>
          Mycoplasma
         </em>
         <em>
          pneumoniae
         </em>
         – Mask within 3 feet (ie, droplet precautions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenovirus – Contact and droplet precautions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         and other multidrug resistant organisms – Special organism precautions; contact and droplet precautions and dedicated patient equipment
        </p>
        <p>
        </p>
        <p>
         Because isolation precautions are different for different pathogens, we favor simplifying the approach for viral respiratory pathogens by placing all patients with suspected viral respiratory tract infection on both contact and droplet precautions. These precautions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care includes ensuring adequate antipyresis, analgesia, respiratory support, and hydration.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Antipyresis and analgesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children hospitalized with pneumonia usually have fever and may have pleuritic chest pain, which can lead to shallow breathing and impaired ability to cough. Administration of antipyretics and/or analgesics (eg,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         ) can be used to keep the child comfortable; opioid analgesia is rarely necessary in children without a chest tube in place. Adequate pain control may promote coughing, which facilitates airway clearance. Antitussives should be avoided as none have been found to be effective in pneumonia [
         <a href="#rid8">
          8
         </a>
         ]. Symptomatic treatment of cough is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">
          "The common cold in children: Management and prevention", section on 'Cough'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Respiratory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children hospitalized with pneumonia should receive ventilatory support as indicated by their clinical condition [
         <a href="#rid1">
          1,2
         </a>
         ]. A supported sitting position may help to expand the lungs and improve respiratory symptoms [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         We suggest that children with oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] &lt;95 percent in room air be treated with supplemental oxygen to maintain oxygen saturation ≥95 percent while they are in respiratory distress. Different thresholds for supplemental oxygen are suggested by other experts (eg, the British Thoracic Society guidelines suggest supplemental oxygenation to maintain oxygenation saturation &gt;92 percent) [
         <a href="#rid2">
          2
         </a>
         ]. Gentle bulb suction of the nares may be helpful in infants and children whose nares are blocked with secretions. Minimal handling seems to reduce oxygen requirements. (See
         <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">
          "Continuous oxygen delivery systems for the acute care of infants, children, and adults"
         </a>
         .)
        </p>
        <p>
         In children who are severely ill, it may be necessary to monitor carbon dioxide tension via blood gas analysis in addition to SpO
         <sub>
          2
         </sub>
         by oximetry. Hypercarbia is an important sign of impending respiratory failure, particularly in the young infant who is tiring but may have preserved oxygenation.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Fluid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who cannot maintain adequate fluid intake because of breathlessness, fatigue, or risk of aspiration [
         <a href="#rid9">
          9
         </a>
         ] may require intravenous (IV) fluid therapy. Nasogastric tubes should be avoided if possible because they may compromise breathing; if necessary, the smallest nasogastric tube possible should be used [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         .)
        </p>
        <p>
         Children with pneumonia are at risk for inappropriate secretion of antidiuretic hormone (SIADH) [
         <a href="#rid10">
          10,11
         </a>
         ]. Serum electrolytes, fluid balance, and urine specific gravity should be monitored if there is clinical suspicion of SIADH [
         <a href="#rid11">
          11
         </a>
         ]. Confirmation of SIADH is discussed separately. Isotonic, rather than hypotonic, IV fluids should be provided if SIADH is suspected. (See
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Pulmonary disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Chest physiotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest physiotherapy is not beneficial for children with uncomplicated community-acquired pneumonia (CAP) [
         <a href="#rid2">
          2
         </a>
         ]. In randomized and observational studies in children and adults, chest physiotherapy had no conclusive effect on length of hospital stay, duration of fever, or radiographic resolution [
         <a href="#rid12">
          12-17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9492623">
         <span class="h2">
          Adjunctive glucocorticoid therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely provide adjunctive glucocorticoid therapy to children hospitalized with pneumonia. Although a systematic review and meta-analysis of two small heterogeneous trials suggested that glucocorticoids reduce clinical failure (defined as death from any cause, radiographic progression, or clinical instability at day 5 to 8) and time to clinical cure, additional studies in children are necessary before glucocorticoids can be routinely recommended [
         <a href="#rid18">
          18-20
         </a>
         ]. A retrospective study evaluating adjunctive glucocorticoid therapy for children being treated for CAP in the outpatient setting found an association between adjunctive glucocorticoid therapy and treatment failure in children without underlying asthma [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Adjunctive glucocorticoids for adults with pneumonia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          EMPIRIC THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt initiation of antimicrobial therapy is crucial in children with community-acquired pneumonia (CAP). The initial treatment of children who are hospitalized with pneumonia is empiric  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ). Factors that must be considered include the spectrum of likely pathogens, antimicrobial susceptibility, simplicity, tolerability, palatability, safety, and cost [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The recommendations of most guidelines are based on in vitro susceptibilities of the most likely pathogen or pathogens, rather than evidence of the superiority of one antibiotic over another. Clinical response to empiric therapy and results of microbiologic studies, when available, help to determine whether additional evaluation or changes in therapy are necessary [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Specific therapy'
         </a>
         below and
         <a class="local">
          'Response to therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Etiologic diagnosis'
         </a>
         .)
        </p>
        <p>
         There are few randomized controlled trials to guide the choice of empiric antibiotics in children with CAP. Decisions regarding empiric therapy are complicated by the substantial overlap in the clinical presentation of bacterial and nonbacterial pneumonias [
         <a href="#rid23">
          23-25
         </a>
         ]. Treatment decisions usually are based upon algorithms that include patient age, epidemiologic and clinical information, and diagnostic laboratory and imaging studies  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. The scope of empiric therapy (ie, narrow or broad) depends upon the severity of illness and presence of complications. Agents other than those suggested in the table may be more appropriate if there are clinical or epidemiologic features strongly suggestive of a specific cause (eg, mediastinal or hilar lymphadenopathy, residence in the central United States, and exposure to caves and/or bat guano suggestive of pulmonary histoplasmosis).
        </p>
        <p>
         Consultation with a specialist in infectious disease may be helpful in children with medication allergies, comorbid conditions, failure of outpatient therapy, or multiple-drug-resistant organisms. Consultation with a pediatric pulmonologist may be helpful in children with recurrent pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">
          "Community-acquired pneumonia in children: Outpatient treatment", section on 'Treatment failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Etiologic clues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain clinical and epidemiologic features can be used to determine the most likely pathogen(s) to aid in decisions regarding empiric therapy. Because these features often overlap, they cannot be used with complete confidence but are helpful in guiding empiric therapy until results of microbiologic tests are available  (
         <a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">
          table 3
         </a>
         ). These features are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Clues to etiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Etiologic clues'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Neonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of neonatal pneumonia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">
          "Neonatal pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Viral pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children younger than three to five years of age who are admitted to the hospital with pneumonia have viral pneumonia (eg, respiratory syncytial virus [RSV]) [
         <a href="#rid26">
          26
         </a>
         ]. This is particularly true in the absence of lobar (or lobular) infiltrate and pleural effusion [
         <a href="#rid4">
          4
         </a>
         ]. Viral pneumonia does not require antibiotic therapy unless a mixed infection or secondary bacterial infection is suspected. (See
         <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">
          "Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6001.html" rel="external">
          "Respiratory syncytial virus infection: Treatment in infants and children"
         </a>
         .)
        </p>
        <p>
         No effective antivirals are available for most viral pneumonias, with a few important exceptions, described below.
        </p>
        <p class="headingAnchor" id="H342058479">
         <span class="h3">
          COVID-19 pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of coronavirus 2019 (COVID-19)-related pneumonia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">
          "COVID-19: Management in children", section on 'Management of hospitalized children'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H275031">
         <span class="h3">
          Influenza pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initiation of antiviral treatment for influenza (eg,
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         ) as soon as possible is recommended for children hospitalized with presumed influenza pneumonia; laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         For children with influenza pneumonia in whom secondary bacterial pneumonia is suspected, empiric antibiotic therapy should include coverage for
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         , including methicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         (MRSA). Coinfection with
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         may be particularly severe and rapidly fatal. (See
         <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">
          "
          <i>
           Staphylococcus aureus
          </i>
          in children: Overview of treatment of invasive infections", section on 'Empiric antimicrobial therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H164277222">
         <span class="h3">
          Other viral pneumonias
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          Acyclovir
         </a>
         can be used in the treatment of pneumonia due to herpes simplex virus or varicella zoster virus.
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          Ganciclovir
         </a>
         can be used in the treatment of pneumonia due to cytomegalovirus (CMV). (See
         <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">
          "Treatment of varicella (chickenpox) infection", section on 'Individuals with complications'
         </a>
         .)
        </p>
        <p>
         Common respiratory viruses may cause serious infections in immunocompromised children and require consideration of antiviral therapy:
         <a class="drug drug_pediatric" data-topicid="12764" href="/z/d/drug information/12764.html" rel="external">
          ribavirin
         </a>
         for RSV or parainfluenza and
         <a class="drug drug_pediatric" data-topicid="13155" href="/z/d/drug information/13155.html" rel="external">
          cidofovir
         </a>
         for adenovirus. Concomitant immunotherapy is an additional consideration:
         <a class="drug drug_pediatric" data-topicid="12672" href="/z/d/drug information/12672.html" rel="external">
          palivizumab
         </a>
         for RSV,
         <a class="drug drug_pediatric" data-topicid="12926" href="/z/d/drug information/12926.html" rel="external">
          CMV immune globulin
         </a>
         for CMV, and intravenous immunoglobulin for the other viral etiologies. (See
         <a class="medical medical_review" href="/z/d/html/8348.html" rel="external">
          "Diagnosis, treatment, and prevention of adenovirus infection", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6001.html" rel="external">
          "Respiratory syncytial virus infection: Treatment in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Uncomplicated bacterial pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         is the most common bacterial cause of pneumonia in children of all ages [
         <a href="#rid4">
          4,27
         </a>
         ]. Other potential bacterial pathogens that may need to be included in empiric therapy for hospitalized children include
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         , including MRSA,
         <em>
          Streptococcus
         </em>
         <em>
          pyogenes
         </em>
         (group A
         <em>
          Streptococcus
         </em>
         ),
         <em>
          Haemophilus
         </em>
         <em>
          influenzae
         </em>
         type b (Hib; if unimmunized), other typeable non-b and nontypeable
         <em>
          H
         </em>
         .
         <em>
          influenzae
         </em>
         , and
         <em>
          Moraxella
         </em>
         <em>
          catarrhalis
         </em>
         [
         <a href="#rid2">
          2,4,27-32
         </a>
         ].
        </p>
        <p>
         The table provides several suggested parenteral empiric antibiotic regimens for
         <strong>
          uncomplicated
         </strong>
         bacterial pneumonia in hospitalized children when
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is not a consideration  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid4">
          4,33,34
         </a>
         ]. The treatment of complicated CAP and severe CAP (particularly when
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is a consideration) are discussed below. (See
         <a class="local">
          'Complicated CAP'
         </a>
         below and
         <a class="local">
          'Severe CAP'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          Ampicillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">
          penicillin G
         </a>
         generally provides adequate coverage for the fully immunized child  (
         <a class="graphic graphic_table graphicRef95852" href="/z/d/graphic/95852.html" rel="external">
          table 4
         </a>
         ) in communities without substantial prevalence of penicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         [
         <a href="#rid1">
          1,35,36
         </a>
         ].
        </p>
        <p>
         We suggest a third-generation cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         ) for children younger than 12 months and those who are not fully immunized because third-generation cephalosporins provide coverage for the beta-lactamase producing pathogens (eg,
         <em>
          H
         </em>
         .
         <em>
          influenzae
         </em>
         and
         <em>
          M
         </em>
         .
         <em>
          catarrhalis
         </em>
         ) that may occur in these children. We also suggest third-generation cephalosporins for children with more severe illness  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ) because third-generation cephalosporins provide coverage for a broader range of pathogens, including penicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         , than
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         [
         <a href="#rid1">
          1,37,38
         </a>
         ].
        </p>
        <p>
         When community-associated-MRSA (CA-MRSA) is considered a potential pathogen for CAP in children, we usually add
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (depending upon local susceptibility patterns). The fifth-generation cephalosporin,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         , is an alternative. In the United States, ceftaroline is available for the treatment of pediatric CAP due to
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         , methicillin-susceptible
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         , and
         <em>
          H
         </em>
         .
         <em>
          influenzae
         </em>
         in children ≥2 months of age [
         <a href="#rid39">
          39
         </a>
         ]. Although ceftaroline has good in vitro activity against MRSA isolates [
         <a href="#rid40">
          40
         </a>
         ] and has been effective in the treatment of pediatric CAP in randomized trials, few children included in the trials had documented MRSA [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
         A macrolide may be added  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) if
         <em>
          M
         </em>
         .
         <em>
          pneumoniae
         </em>
         ,
         <em>
          Chlamydia
         </em>
         <em>
          pneumoniae
         </em>
         , or legionellosis is suspected, although the benefits of combination therapy are uncertain. In a prospective population-based study of 1418 children hospitalized with radiographically confirmed CAP, the addition of a macrolide to beta-lactam antimicrobial therapy was not associated with decreased length of stay, intensive care admission, rehospitalization, or self-reported recovery [
         <a href="#rid43">
          43
         </a>
         ]. In subgroup analysis, combination therapy was not associated with decreased length of stay in children in whom atypical bacteria were detected, children older than five years, children admitted to the intensive care unit (ICU), or children with wheezing. (See
         <a class="local">
          'Atypical pneumonia'
         </a>
         below.)
        </p>
        <p>
         We suggest that children who require hospitalization for treatment of CAP be treated initially with parenteral antibiotics. However, oral
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         may be an alternative for infants and children fully immunized against Hib and
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         with uncomplicated pneumonia that is not thought to be due to
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         [
         <a href="#rid44">
          44
         </a>
         ]. In a multicenter randomized trial, treatment with amoxicillin was equivalent to treatment with
         <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">
          penicillin G
         </a>
         in children with CAP who required hospital admission but did not have wheezing, hypotension, chronic pulmonary conditions (other than asthma), immunodeficiency, pleural effusion requiring drainage, or oxygen saturations &lt;85 percent in room air [
         <a href="#rid45">
          45
         </a>
         ]. The British Thoracic Society guidelines suggest that oral antibiotics are safe and effective even for children with severe pneumonia as long as they are able to tolerate oral fluids, are not vomiting, and do not have signs of septicemia or complicated pneumonia [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Atypical pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical bacterial pathogens include
         <em>
          C
         </em>
         .
         <em>
          trachomatis
         </em>
         in afebrile infants, and
         <em>
          M
         </em>
         .
         <em>
          pneumoniae
         </em>
         and
         <em>
          C
         </em>
         .
         <em>
          pneumoniae
         </em>
         in older children and adolescents. The table provides several suggested empiric regimens for atypical bacterial pneumonia in hospitalized children  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid4">
          4,33
         </a>
         ].
        </p>
        <p>
         For children older than four years with suspected atypical pneumonia, coverage for typical bacterial pathogens (eg,
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         or a third-generation cephalosporin) may be added to empiric coverage for atypical pathogens if there is strong evidence of a bacterial cause. Strong evidence of a bacterial cause includes white blood cell count &gt;15,000/microL, C-reactive protein &gt;35 to 60 mg/L (3.5 to 6 mg/dL), chills, or no response to outpatient therapy with a macrolide or
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         [
         <a href="#rid4">
          4,46
         </a>
         ].
        </p>
        <p>
         Fluoroquinolones (eg,
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          moxifloxacin
         </a>
         ) may be reasonable empiric therapy for the older child and adolescent with suspected atypical pneumonia who could possibly have pneumococcal pneumonia. The fluoroquinolones also may be used in the older child or adolescent who is unable to receive beta-lactam antibiotics (eg, history of immunoglobulin [Ig]E-mediated reaction or serious delayed reaction  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 5
         </a>
         )). In addition to their excellent gram-negative spectrum, the fluoroquinolones are active against a number of the pathogens responsible for CAP, including beta-lactam-susceptible and nonsusceptible
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         ,
         <em>
          M
         </em>
         .
         <em>
          pneumoniae
         </em>
         (including macrolide-resistant
         <em>
          M
         </em>
         .
         <em>
          pneumoniae)
         </em>
         , and
         <em>
          C
         </em>
         .
         <em>
          pneumoniae
         </em>
         [
         <a href="#rid47">
          47
         </a>
         ]. However,
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         resistant to levofloxacin have been identified [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Severe CAP
         </span>
        </p>
        <p class="headingAnchor" id="H687567972">
         <span class="h3">
          Severe CAP not requiring ICU admission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with severe CAP who do not require admission to the ICU  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ) may benefit from combination empiric therapy with a macrolide and a beta-lactam antibiotic (eg,
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         or third-generation cephalosporin)  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ). Combination therapy improves coverage for resistant organisms and mixed bacterial/atypical bacterial infections.
        </p>
        <p>
         If
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is an etiologic consideration, options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adding either
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (depending upon local susceptibility patterns) to the combination macrolide and beta-lactam, or
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Switching from the combination macrolide and beta-lactam to
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
        </p>
        <p>
        </p>
        <p>
         Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. Invasive diagnostic testing, including bronchoscopy with bronchoalveolar lavage, may be necessary for specific microbiologic diagnosis. (See
         <a class="local">
          'Uncomplicated bacterial pneumonia'
         </a>
         above and
         <a class="local">
          'Atypical pneumonia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Invasive studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Severe CAP requiring ICU admission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who are admitted to the ICU for serious or life-threatening infections require broad-spectrum empiric coverage that addresses potential beta-lactam resistance and CA-MRSA. (See
         <a class="local">
          'Indications for intensive care'
         </a>
         above.)
        </p>
        <p>
         A suggested regimen for such children may include  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid49">
          49-51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 6
         </a>
         ),
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third-generation cephalosporin (
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         150 mg/kg per day IV in four divided doses up to a maximum of 8 g/day
         <strong>
          or
         </strong>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         100 mg/kg per day IV in two divided doses up to a maximum dose of 4 g/day),
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          Azithromycin
         </a>
         10 mg/kg once per day IV for two days (maximum 500 mg/day), followed by 5 mg/kg once per day IV (maximum 250 mg/day),
         <strong>
          and possibly
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          Nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         150 to 200 mg/kg per day IV in four divided doses; maximum 12 g/day if
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is likely (methicillin-susceptible
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is more rapidly killed by nafcillin than by
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ),
         <strong>
          and possibly
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiviral therapy for influenza, if the child is hospitalized during influenza season; laboratory confirmation of influenza should not delay initiation of antiviral therapy (see
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         This combination is necessary because of reports of treatment failure resulting from treatment of nonsusceptible
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         with beta-lactams,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         resistance among
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         (which, however, is becoming less prevalent), and concern for MRSA [
         <a href="#rid49">
          49
         </a>
         ]. Virtually all strains of MRSA are susceptible to
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">
          "
          <i>
           Staphylococcus aureus
          </i>
          in children: Overview of treatment of invasive infections", section on 'MRSA infections'
         </a>
         .)
        </p>
        <p>
         When treating with
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         , renal function and serum trough levels or dosing to achieve an area under the curve/minimum inhibitory concentration (AUC:MIC) ratio &gt;400 should be monitored in an attempt to assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20 microgram/mL have been suggested to improve clinical outcomes for complicated infections due to
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         [
         <a href="#rid51">
          51-53
         </a>
         ]. Similar trough levels may not be needed in children to achieve an AUC:MIC &gt;400, and further studies are needed to evaluate the clinical effectiveness and safety of these dosing recommendations in children [
         <a href="#rid53">
          53-58
         </a>
         ].
        </p>
        <p>
         For children in whom
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is likely,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         could be substituted for
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         in the above regimen. Linezolid is an oxazolidinone antibiotic with activity against gram-positive cocci, including beta-lactam-resistant
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         and MRSA. However, against
         <em>
          S. aureus
         </em>
         it is only bacteriostatic. Linezolid is dosed according to age as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;12 years – 10 mg/kg per dose IV every 8 hours (maximum 600 mg/dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≥12 years – 600 mg every 12 hours
        </p>
        <p>
        </p>
        <p>
         An alternative non-vancomycin-containing regimen for children in whom
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is a consideration consists of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          Ceftaroline
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥2 months and &lt;2 years – 8 mg/kg per dose IV every 8 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥2 years and &lt;18 years:
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight ≤33 kg – 12 mg/kg per dose IV every 8 hours
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &gt;33 kg – 400 mg/dose IV every 8 hours or 600 mg/dose IV every 12 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥18 years – 600 mg/dose IV every 12 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plus
         </strong>
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         10 mg/kg once per day IV for two days (maximum 500 mg/day), followed by 5 mg/kg once per day IV (maximum 250 mg/day),
         <strong>
          and possibly
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiviral therapy for influenza, if the child is hospitalized during influenza season; laboratory confirmation of influenza should not delay initiation of antiviral therapy (see
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H96270984">
         <span class="h2">
          Complicated CAP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complicated CAP (eg, parapneumonic effusion, necrotizing process, lung abscess) requires a broader spectrum of antibiotic coverage if etiologies other than
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         are being considered. The expanded spectrum should include coverage for beta-lactam-resistant isolates including CA-MRSA. Coverage for anaerobes and gram-negative organisms also may be necessary for children with lung abscess [
         <a href="#rid59">
          59
         </a>
         ]. Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children"
         </a>
         .)
        </p>
        <p>
         Complicated CAP requires a prolonged course of antimicrobial therapy, usually initiated parenterally [
         <a href="#rid60">
          60
         </a>
         ]. Appropriate regimens may include [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Either
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         100 mg/kg IV in two divided doses (maximum 4 g/day) or
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         150 mg/kg per day IV in four divided doses (maximum 8 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         or anaerobes are a consideration, add
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         30 to 40 mg/kg per day IV in three or four divided doses (maximum 2.7 g/day).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 6
         </a>
         ) is an alternative to
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         if the patient is allergic to clindamycin or if clindamycin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is prevalent in the community. The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing vancomycin varies from center to center, usually ranging from 10 to 25 percent, in an effort to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, severity of illness, renal function and/or use of other nephrotoxic agents, and turnaround time for susceptibilities. When treating with vancomycin, renal function and serum trough levels or dosing to achieve an AUC:MIC ratio of &gt;400 should be monitored in an attempt to assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20 microgram/mL have been suggested to improve clinical outcomes for complicated infections due to
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         [
         <a href="#rid51">
          51-53
         </a>
         ]. Similar trough levels may not be needed in children to achieve an AUC:MIC &gt;400, and further studies are needed to evaluate the clinical effectiveness and safety of these dosing recommendations in children [
         <a href="#rid53">
          53-58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">
          "
          <i>
           Staphylococcus aureus
          </i>
          in children: Overview of treatment of invasive infections", section on 'MRSA infections'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monotherapy with
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         is an alternative if
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         is a consideration:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥2 months and &lt;2 years – 8 mg/kg per dose IV every 8 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥2 years and &lt;18 years:
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight ≤33 kg – 12 mg/kg per dose IV every 8 hours
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &gt;33 kg – 400 mg/dose IV every 8 hours or 600 mg/dose IV every 12 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥18 years – 600 mg/dose IV every 12 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a multicenter randomized trial in 40 children with complicated community-acquired bacterial pneumonia (only one had documented MRSA), clinical cure rates at the end of treatment were similar with
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         monotherapy and combination
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (approximately 80 percent) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with lung abscess that is thought to be secondary to aspiration,
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          ampicillin-sulbactam
         </a>
         150 to 200 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         component IV in four divided doses (maximum 8 g/day for the ampicillin component) alone may be effective. (See
         <a class="local">
          'Aspiration pneumonia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The duration of therapy and other considerations in the management of complicated pneumonia depend upon the type of complication:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parapneumonic effusion/empyema
         </strong>
         – The treatment of parapneumonic effusion and empyema is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Necrotizing pneumonia
         </strong>
         – Treatment of necrotizing pneumonia requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response but is usually a total of four weeks or two weeks after the patient is afebrile and has improved clinically. Interventional procedures (eg, percutaneous drainage catheter placement) should be performed cautiously in children with necrotizing pneumonia; such procedures increase the risk of complications, such as the development of bronchopleural fistulae [
         <a href="#rid59">
          59,61-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung abscess
         </strong>
         – Treatment of lung abscess requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response and radiographic resolution of the abscess or stabilization of a small lesion. The usual course is a total of three to four weeks or two weeks after the patient is afebrile and has clinical improvement [
         <a href="#rid60">
          60
         </a>
         ]. The average duration of fever is four to eight days. Antibiotic therapy can be changed from the parenteral to the oral route when the child is improving clinically and is afebrile. Eighty to 90 percent of lung abscesses in children resolve with antibiotic therapy alone and spontaneous drainage through the tracheobronchial tree, provided that any bronchial obstruction is removed [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In cases that fail to resolve with antibiotics alone, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit without the increased risk of complications that occurs in children with necrotizing pneumonia [
         <a href="#rid59">
          59,61,65,66
         </a>
         ]. Percutaneous drainage may be warranted in children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy [
         <a href="#rid67">
          67
         </a>
         ]. At least three weeks of IV antibiotic therapy should be delivered before lobectomy is considered for treatment failure [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumatocele
         </strong>
         – Most pneumatoceles involute spontaneously [
         <a href="#rid69">
          69-71
         </a>
         ]. However, on occasion, pneumatoceles may result in pneumothorax [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Hospital-acquired pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric treatment of hospital-acquired pneumonia should include coverage for
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         , Enterobacteriaceae,
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         , and anaerobes. Acceptable broad spectrum regimens usually include an aminoglycoside (for gram-negative pathogens) and another agent to address gram-positive pathogens and anaerobes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycoside (usually
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ;
         <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">
          amikacin
         </a>
         if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies)
         <strong>
          plus one of the following
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          Piperacillin-tazobactam
         </a>
         300 mg/kg per day IV in four divided doses up to a maximum of 12 g/day,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          Meropenem
         </a>
         60 mg/kg per day IV in three divided doses, up to a maximum of 6 g/day if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          Ceftazidime
         </a>
         125 to 150 mg/kg per day in three divided doses; maximum of 6 g/day,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          Cefepime
         </a>
         150 mg/kg per day in three divided doses; maximum of 4 g/day,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          Clindamycin
         </a>
         30 to 40 mg/kg per day in three or four divided doses; maximum 2.7 g/day (for patients unable to receive beta-lactam antibiotics [eg, history of IgE-mediated reaction or severe delayed hypersensitivity reaction  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 5
         </a>
         )])
        </p>
        <p>
        </p>
        <p>
         The combination of
         <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">
          amikacin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         should be used if extended-spectrum beta-lactamase-producing gram-negative rods are a consideration. The combination of amikacin and either meropenem or
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         should be used if AmpC beta-lactamase-producing gram-negative rods are a consideration.
        </p>
        <p>
         The cephalosporin/aminoglycoside combination lacks anaerobic coverage, so it should
         <strong>
          not
         </strong>
         be used when aspiration pneumonia is a possibility. (See
         <a class="local">
          'Aspiration pneumonia'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         should be added to the empiric regimen if MRSA is a consideration. An agent other than
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         should be chosen as the second agent, if feasible, when vancomycin is added because the combination of these two drugs has been associated with increased risk of acute kidney injury [
         <a href="#rid73">
          73,74
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          Ceftaroline
         </a>
         is an alternative to vancomycin if MRSA is a consideration.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Aspiration pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric antibiotic regimens for community-acquired aspiration pneumonia must cover oral anaerobes. Appropriate antibiotic regimens for hospitalized children include [
         <a href="#rid67">
          67
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          Ampicillin-sulbactam
         </a>
         150 to 200 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         component IV in four divided doses; maximum 8 g/day of the ampicillin component,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          Clindamycin
         </a>
         30 to 40 mg/kg per day IV in three or four divided doses to a maximum of 2.7 g/day if MRSA etiology is suspected or for patients unable to receive beta-lactam antibiotics (eg, history of IgE-mediated reaction or severe delayed hypersensitivity reaction  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 5
         </a>
         )).
        </p>
        <p>
        </p>
        <p>
         In neurologically compromised older adolescents prone to aspiration events, empiric treatment for CAP with a fluoroquinolone like
         <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">
          moxifloxacin
         </a>
         (400 mg once daily) may be reasonable. Moxifloxacin has activity against anaerobic bacteria, as well as the usual treatable causes of CAP (
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         ,
         <em>
          M
         </em>
         .
         <em>
          pneumoniae
         </em>
         , and
         <em>
          C
         </em>
         .
         <em>
          pneumoniae)
         </em>
         .
        </p>
        <p>
         Appropriate antibiotic regimens for children with health care-associated aspiration who are known to be colonized with unusual gram-negative pathogens (eg,
         <em>
          Klebsiella
         </em>
         <em>
          pneumoniae
         </em>
         ) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          Piperacillin-tazobactam
         </a>
         300 mg/kg per day IV in four divided doses up to a maximum of 12 g/day,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          Meropenem
         </a>
         60 mg/kg per day IV in three divided doses, up to a maximum of 6 g/day
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         should be added to the empiric regimen if MRSA is a consideration.
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          Meropenem
         </a>
         may be preferred for gram-negative coverage if vancomycin is added because the combination of vancomycin and
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         has been associated with increased risk of acute kidney injury [
         <a href="#rid73">
          73,74
         </a>
         ]. However, this risk must be weighed against the development of meropenem resistance, particularly in closed units.
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          Ceftaroline
         </a>
         is an alternative to vancomycin if MRSA is a consideration.
        </p>
        <p>
         Patients with contraindications to beta-lactam antibiotics (eg, history of IgE-mediated reaction or severe delayed hypersensitivity reaction  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 5
         </a>
         )) can be treated with a combination of
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         and an aminoglycoside.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Immunocompromised host
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric treatment for pneumonia in immunocompromised hosts also requires broad-spectrum gram-positive and gram-negative coverage, similar to that required for hospital-acquired pneumonia, with the addition of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         if MRSA is considered, and possibly
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         for
         <em>
          Pneumocystis
         </em>
         <em>
          jirovecii
         </em>
         (formerly
         <em>
          P
         </em>
         .
         <em>
          carinii
         </em>
         ). Empiric regimens may need to be modified once results of cultures and antibiotic susceptibility testing are available. Invasive testing may be required to obtain a satisfactory specimen in such patients (see
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Invasive studies'
         </a>
         ). Treatment of CAP in the immunocompromised host should occur in consultation with an infectious disease specialist.
        </p>
        <p>
         An aggressive approach to specific microbial diagnosis is indicated in immunocompromised hosts with clinically significant pneumonias. For patients with an endotracheal tube in place, specific microbial diagnosis may involve early flexible bronchoscopy for bronchoalveolar lavage with viral, fungal, and bacterial diagnostic studies. Although the protected specimen brush technique has been utilized in some settings, quantitative bacterial cultures are more commonly used to differentiate colonization from true lower respiratory tract infection. (See
         <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">
          "Flexible bronchoscopy in adults: Indications and contraindications", section on 'Diagnostic indications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">
          "Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SPECIFIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once results of microbiologic tests are available, antimicrobial therapy can be directed toward the responsible pathogen or pathogens. Specific antimicrobial and/or supportive therapy for the pathogens that commonly cause community-acquired pneumonia (CAP) in children is discussed in the topic reviews listed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/6060.html" rel="external">
          "Pneumococcal pneumonia in children", section on 'Specific therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group A
         <em>
          Streptococcus
         </em>
         –
         <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">
          Penicillin G
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         are the preferred parenteral agents for pneumonia caused by group A
         <em>
          Streptococcus
         </em>
         ; the doses are as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">
          Penicillin G
         </a>
         100,000 to 250,000 units/kg per day intravenously (IV) divided in four or six doses
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          Ampicillin
         </a>
         200 mg/kg per day IV divided in four doses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternative parenteral agents include
         <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">
          cefazolin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (if susceptible), and
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (for children unable to receive beta-lactam antibiotics [eg, history of IgE-mediated reaction or severe delayed hypersensitivity reaction  (
         <a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">
          table 5
         </a>
         )]) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          Amoxicillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12689" href="/z/d/drug information/12689.html" rel="external">
          penicillin V
         </a>
         are the preferred oral agents; the doses are as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          Amoxicillin
         </a>
         50 to 75 mg/kg per day orally divided in two doses (maximum 4 g/day)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12689" href="/z/d/drug information/12689.html" rel="external">
          Penicillin V
         </a>
         50 to 75 mg/kg per day orally divided in three doses (maximum 2 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternative oral agents include
         <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">
          cephalexin
         </a>
         75 to 100 mg/kg per day in three or four divided doses (maximum 4 g/day) or
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (if susceptible) 40 mg/kg per day orally divided in three doses (maximum 1.8 g/day) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Haemophilus
         </em>
         <em>
          influenzae
         </em>
         (typeable or nontypeable) (see
         <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">
          "Epidemiology, clinical manifestations, diagnosis, and treatment of
          <i>
           Haemophilus influenzae
          </i>
          ", section on 'Directed treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          M
         </em>
         .
         <em>
          pneumoniae
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in children", section on 'Management'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          C
         </em>
         .
         <em>
          pneumoniae
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/5957.html" rel="external">
          "Pneumonia caused by
          <i>
           Chlamydia pneumoniae
          </i>
          in children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-susceptible
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         (MSSA) – MSSA pneumonia may be treated with
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">
          cefazolin
         </a>
         [
         <a href="#rid1">
          1,4
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         (MRSA) (see
         <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">
          "
          <i>
           Staphylococcus aureus
          </i>
          in children: Overview of treatment of invasive infections", section on 'Definitive antimicrobial therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory syncytial virus (see
         <a class="medical medical_review" href="/z/d/html/6001.html" rel="external">
          "Respiratory syncytial virus infection: Treatment in infants and children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza (see
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parainfluenza (see
         <a class="medical medical_review" href="/z/d/html/5975.html" rel="external">
          "Parainfluenza viruses in children", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenovirus (see
         <a class="medical medical_review" href="/z/d/html/8348.html" rel="external">
          "Diagnosis, treatment, and prevention of adenovirus infection", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human metapneumovirus (see
         <a class="medical medical_review" href="/z/d/html/8311.html" rel="external">
          "Human metapneumovirus infections", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          DURATION OF TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Parenteral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data to guide decisions about the duration of parenteral therapy for community-acquired pneumonia (CAP) [
         <a href="#rid2">
          2,75
         </a>
         ]. It is common to switch to oral therapy in patients who have received parenteral antibiotics when the patient has become afebrile for 24 to 48 hours and is not having emesis [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Total duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few randomized controlled trials to guide decisions about the appropriate duration of antimicrobial therapy for radiographically confirmed childhood pneumonia [
         <a href="#rid2">
          2
         </a>
         ]. Clinical practice assigns duration of therapy according to the host, causative agent, and severity.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncomplicated cases
         </strong>
         – For children hospitalized with uncomplicated pneumonia, we generally treat with a seven-day course of combined parenteral and oral therapy, although a course of five to seven days may also be effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although evidence from randomized trials in children is lacking, there is some evidence to support five to seven days of therapy. In a single-center observational study in children ≥6 months of age who were hospitalized with uncomplicated community-acquired pneumonia (CAP), rates of treatment failure were similar among those who received antibiotic therapy for 5 to 7 days and 8 to 14 days (3 versus 6 percent, odds ratio 0.48, 95% CI 0.18-1.20) [
         <a href="#rid77">
          77
         </a>
         ]. Treatment failure was defined as a composite of unanticipated emergency department or outpatient visits, readmission, or death within 30 days after completion of antibiotics. Randomized trials in adult patients with mild to moderate CAP also suggest that outcomes in patients treated for less than seven days are similar to those in patients treated longer. These trials are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting", section on 'Duration of therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complicated cases
         </strong>
         – Treatment of complications, such as necrotizing pneumonia and lung abscess, requires a prolonged course of antibiotic therapy, usually initiated parenterally. The duration is determined by the clinical response but usually is either a total of three to four weeks or a total of two weeks after the patient is afebrile and has improved clinically. Some infectious diseases specialists use an erythrocyte sedimentation rate value of &lt;20 mm/hour as a laboratory indicator that the duration of therapy has been sufficient. (See
         <a class="local">
          'Complicated CAP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          RESPONSE TO THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following clinical parameters can be monitored to assess response to treatment [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temperature
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory rate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart rate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral capillary oxygen saturation (SpO
         <sub>
          2
         </sub>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Work of breathing (eg, retractions, nasal flaring, grunting)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest examination (extent of abnormal or absent breath sounds; extent of dullness to percussion)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to maintain oral intake and hydration
        </p>
        <p>
        </p>
        <p>
         The frequency of monitoring depends upon the severity of illness. In patients who are receiving oxygen supplementation, oxygen saturation should be evaluated regularly. Evaluation for hypercarbia may be necessary in children with severe respiratory distress, as oxygenation may be preserved.
        </p>
        <p>
         The respiratory status of children with community-acquired pneumonia (CAP) who are appropriately treated should improve within 48 to 72 hours [
         <a href="#rid1">
          1
         </a>
         ]. However, fevers may persist for several days after initiation of appropriate therapy [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children who fail to improve as anticipated, the following possibilities must be considered [
         <a href="#rid1">
          1,2,78,79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternative or coincident diagnoses (eg, foreign body aspiration) (see
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ineffective antibiotic coverage (lack of coverage for the actual etiology or resistant organism)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Development of complications (see
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying immunodeficiency condition
        </p>
        <p>
        </p>
        <p>
         The history should be reviewed with special attention to the possibility of foreign body aspiration and geographic or environmental exposures associated with pathogens not treated by the empiric regimen  (
         <a class="graphic graphic_table graphicRef52510" href="/z/d/graphic/52510.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
         Changes in laboratory parameters (eg, peripheral white blood cell count, inflammatory markers [if obtained initially]) may provide information about disease progression. Repeat radiographs or additional imaging studies can help to assess the degree of parenchymal involvement and evaluate for complications or anatomic abnormalities [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">
          "Pneumonia in children: Epidemiology, pathogenesis, and etiology", section on 'Etiologic agents'
         </a>
         .)
        </p>
        <p>
         Depending upon the severity of illness, more aggressive attempts may need to be made to establish a microbiologic diagnosis (eg, induced sputum [
         <a href="#rid80">
          80
         </a>
         ], bronchoscopy with bronchoalveolar lavage, percutaneous needle aspiration, or lung biopsy). In children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit [
         <a href="#rid61">
          61,65-67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">
          "Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Invasive studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          DISCHARGE CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discharge criteria for children who have been admitted to the hospital with community-acquired pneumonia (CAP) have not been standardized, but typically include [
         <a href="#rid1">
          1,67
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement of vital signs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to maintain adequate fluid and nutrition orally
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to maintain oxygen saturation ≥90 percent in room air
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement in respiratory status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overall clinical improvement including level of activity, appetite, and decreased fever for at least 12 to 24 hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stable and/or baseline mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caregivers' ability to administer and child's ability to comply with home antibiotic regimen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Safe and compliant home environment
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h2">
          Outpatient parenteral antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outpatient parenteral antimicrobial therapy (OPAT) is an option for selected patients who require prolonged treatment (usually for complicated CAP that for some reason cannot be treated with an oral antibiotic) and have stabilized clinically [
         <a href="#rid67">
          67,81,82
         </a>
         ]. Eligibility for OPAT requires a suitable home environment and a pharmacologic agent with a reasonable dosing schedule [
         <a href="#rid83">
          83
         </a>
         ]. Decisions regarding OPAT should involve the caregivers, an infectious disease specialist (or clinician knowledgeable about the use of antimicrobial agents in OPAT), a hospital pharmacist, and the primary care provider. The services of a visiting nurse may be required for home visits, education and observation of caregiver administration, and/or obtaining blood samples for therapeutic monitoring.
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          FOLLOW-UP
         </span>
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h2">
          Clinical course
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with pneumonia should be seen by their primary care provider soon after discharge to ensure that clinical improvement continues and antibiotic therapy is being taken as prescribed [
         <a href="#rid67">
          67
         </a>
         ]. Decisions regarding the timing of clinical follow-up should involve the child's primary care provider and the clinical status of the child at the time of discharge.
        </p>
        <p>
         Children who are appropriately treated for pneumonia should gradually improve with time. Cough may persist for as long as three to four months after viral pneumonia or pertussis. Children who are recovering from typical or atypical bacterial pneumonia may continue to cough for several weeks and have moderate dyspnea on exertion for two to three months [
         <a href="#rid84">
          84
         </a>
         ]. Symptomatic treatment of cough is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">
          "The common cold in children: Management and prevention", section on 'Cough'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h2">
          Radiographs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follow-up radiographs are not necessary in asymptomatic children with uncomplicated community-acquired pneumonia (CAP), including round pneumonia [
         <a href="#rid85">
          85
         </a>
         ]. However, in children with complicated CAP or CAP that required intervention, follow-up radiographs help to ensure resolution [
         <a href="#rid2">
          2,86
         </a>
         ]. Follow-up radiographs also may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates [
         <a href="#rid2">
          2,67,87
         </a>
         ]. When follow-up radiographs are indicated, they should be obtained two to three weeks after hospital discharge [
         <a href="#rid67">
          67,88
         </a>
         ]. Other conditions that should be considered if symptoms persist in children with round pneumonia include congenital lung sequestration, pulmonary arteriovenous malformation, metastatic Wilms tumor, cavitary necrosis, pleural pseudocyst, and primary lung carcinoma [
         <a href="#rid85">
          85,87,89-92
         </a>
         ].
        </p>
        <p>
         Several studies have evaluated the utility of follow-up radiographs in cohorts of children with acute radiologically proven CAP [
         <a href="#rid93">
          93-98
         </a>
         ]. Three of the studies included clinical as well as radiologic follow-up at three to seven weeks after initial diagnosis [
         <a href="#rid93">
          93-96
         </a>
         ]. In each of these studies, follow-up radiographs were normal or improved in asymptomatic children. Residual radiographic findings, even when present, did not result in additional therapy.
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most otherwise healthy children with pneumonia recover without sequelae, even if the pneumonia is complicated [
         <a href="#rid62">
          62,63,67,99
         </a>
         ]. In a multicenter cohort study, approximately 3 percent of 82,566 children hospitalized with pneumonia were readmitted with pneumonia within 30 days of discharge; 8 percent were readmitted for any reason. Readmission was more common among children younger than one year and children with chronic medical conditions [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Although some data suggest that nearly one-half of children who are hospitalized for viral pneumonia have symptoms of asthma five years after hospitalization, it is not clear whether this is related to unrecognized asthma at the time of presentation with pneumonia or a tendency to develop asthma after community-acquired viral pneumonia [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p>
         The overall pneumonia mortality rate in developed countries is &lt;1 per 1000 per year [
         <a href="#rid26">
          26,103
         </a>
         ]. Pneumococcal pneumonia case fatality rates (not adjusted for comorbid conditions) for children in the United States were estimated to be 4 percent in children younger than two years and 2 percent in children 2 to 17 years before the introduction of pneumococcal conjugate vaccines [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         The introduction of pneumococcal conjugate vaccines has resulted in a dramatic reduction (37 to 80 percent) in invasive disease and mortality rates in the countries in which they have been introduced [
         <a href="#rid105">
          105
         </a>
         ]. However, pneumococcal pneumonia mortality rates have not been specifically examined. Data from the United States Pediatric Multicenter Pneumococcal Surveillance Study Group demonstrated overall pneumococcal mortality rates of 1 percent after the introduction of PCV7 (during 2006 to 2009) and 0 percent after the introduction of
         <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">
          PCV13
         </a>
         (during 2011 to 2014) [
         <a href="#rid106">
          106
         </a>
         ]. In a study from eastern Gambia, introduction of a nine-valent pneumococcal conjugate vaccine resulted in reduced all-cause mortality (25.2 versus 30.1 per 1000 child-years, a 16 percent reduction) [
         <a href="#rid107">
          107
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children", section on 'Efficacy and effectiveness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2762175865">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">
          "Society guideline links: Pediatric pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8578304">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17120.html" rel="external">
          "Patient education: Pneumonia in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalization and supportive care
         </strong>
         – The decision to hospitalize a child with community-acquired pneumonia (CAP) must be individualized and is based upon age, underlying medical problems, and severity of illness  (
         <a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CAP can be caused by a variety of microbial agents, requiring a variety of infection-control measures. (See
         <a class="local">
          'Infection control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Supportive care for children hospitalized with pneumonia includes provision of adequate respiratory support, hydration, antipyresis, and analgesia. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric antimicrobial therapy
         </strong>
         – Children with CAP who are hospitalized are treated empirically until information from the microbiologic evaluation is available to direct therapy toward a specific pathogen. Decisions regarding empiric antimicrobial therapy for CAP in children are usually based upon age, unless there are other overriding epidemiologic or clinical factors to suggest a specific etiologic agent  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">
          "Pneumonia in children: Epidemiology, pathogenesis, and etiology", section on 'Etiologic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We recommend that empiric antibiotic therapy for presumed bacterial pneumonia in hospitalized children include coverage for
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Uncomplicated bacterial pneumonia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Extended empiric coverage may be indicated for children with complicated or severe pneumonia, particularly those who require admission to an intensive care unit (ICU)  (
         <a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="local">
          'Complicated CAP'
         </a>
         above and
         <a class="local">
          'Severe CAP requiring ICU admission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific antimicrobial therapy
         </strong>
         – When results of microbiologic tests are available, antibiotic therapy can be directed toward the specific pathogen recovered. (See
         <a class="local">
          'Specific therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Switch to oral therapy
         </strong>
         – Oral therapy typically is initiated when the patient has been afebrile for 24 to 48 hours and can tolerate oral intake. The total duration of antibiotic therapy is usually seven days for uncomplicated CAP, although a course of five to seven days may also be effective. Up to four weeks of antimicrobial therapy may be necessary for complicated CAP. (See
         <a class="local">
          'Duration of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment failure
         </strong>
         – The respiratory status of children receiving appropriate therapy for CAP should improve within 48 to 72 hours. Children who fail to improve as anticipated may be receiving inadequate antibiotic therapy, have developed complications, or have an alternative or coincident diagnosis. (See
         <a class="local">
          'Treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course and follow-up
         </strong>
         – Children recovering from CAP may continue to have cough for several weeks to four months, depending upon the etiology. Those recovering from typical or atypical bacterial pneumonia may have moderate dyspnea on exertion for two to three months. (See
         <a class="local">
          'Clinical course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Follow-up radiographs are not necessary in asymptomatic children with uncomplicated CAP. However, in children with complicated CAP or CAP that required intervention, follow-up radiographs help to ensure resolution. Follow-up radiographs two to three weeks after completion of therapy may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates. (See
         <a class="local">
          'Radiographs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most otherwise healthy children who develop pneumonia recover without any long-term sequelae. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell G. Community acquired pneumonia. Arch Dis Child 2001; 85:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duncan H, Hutchison J, Parshuram CS. The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children. J Crit Care 2006; 21:271.
          </a>
         </li>
         <li class="breakAll">
          Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. http://www.cdc.gov/hicpac/2007ip/2007isolationprecautions.html (Accessed on September 25, 2011).
         </li>
         <li class="breakAll">
          Siegel JD, Rhinehart E, Jackson M, Chiarello, L. Management of multidrug-resistant organisms in healthcare settings, 2006. http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf (Accessed on July 17, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 2014; :CD006088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoshoo V, Edell D. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics 1999; 104:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhi S, Dhawan A. Frequency and significance of electrolyte abnormalities in pneumonia. Indian Pediatr 1992; 29:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhawan A, Narang A, Singhi S. Hyponatraemia and the inappropriate ADH syndrome in pneumonia. Ann Trop Paediatr 1992; 12:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton S, Bejstedt M, Vedin L. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 290:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A. Chest physical therapy for children with pneumonia. J Am Osteopath Assoc 1978; 78:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stapleton T. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 291:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paludo C, Zhang L, Lincho CS, et al. Chest physical therapy for children hospitalised with acute pneumonia: a randomised controlled trial. Thorax 2008; 63:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukrafka JL, Fuchs SC, Fischer GB, et al. Chest physiotherapy in paediatric patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Arch Dis Child 2012; 97:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaves GS, Freitas DA, Santino TA, et al. Chest physiotherapy for pneumonia in children. Cochrane Database Syst Rev 2019; 1:CD010277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2014; 49:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagy B, Gaspar I, Papp A, et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatr Pulmonol 2013; 48:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017; 12:CD007720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambroggio L, Test M, Metlay JP, et al. Adjunct Systemic Corticosteroid Therapy in Children With Community-Acquired Pneumonia in the Outpatient Setting. J Pediatric Infect Dis Soc 2015; 4:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004; 43:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friis B, Andersen P, Brenøe E, et al. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. Arch Dis Child 1984; 59:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juvén T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korppi M, Heiskanen-Kosma T, Jalonen E, et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 1993; 152:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J 1998; 17:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo M, McCracken GH Jr. Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia. Pediatr Infect Dis J 1994; 13:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond P, Clark J, Wheeler J, et al. Community acquired pneumonia--a prospective UK study. Arch Dis Child 2000; 83:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr Infect Dis J 2002; 21:592.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.876.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics 2014; 133:e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998; 132:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999; 29:462.
          </a>
         </li>
         <li class="breakAll">
          Teflaro (ceftaroline fosamil) injection. United States Prescribing Information. Revised September, 2019. US Food &amp; Drug Administration. (Available online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm; accessed February 27, 2020.).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. Pediatr Infect Dis J 2017; 36:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J 2016; 35:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumer JL, Ghonghadze T, Cannavino C, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J 2016; 35:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams DJ, Edwards KM, Self WH, et al. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia. JAMA Pediatr 2017; 171:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronman MP, Hersh AL, Newland JG, Gerber JS. Getting Over Our Inpatient Oral Antibiotic Aversion. Pediatrics 2018; 142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax 2007; 62:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. Pediatr Infect Dis J 2008; 27:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL, Mason EO Jr, Barson WJ, et al. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001; 20:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS. Old and new antibiotics for pediatric pneumonia. Semin Respir Infect 2002; 17:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moffett BS, Kim S, Edwards M. Vancomycin nephrotoxicity may be overstated. J Pediatr 2011; 158:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit. Pharmacotherapy 2013; 33:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J 2013; 32:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chhim RF, Arnold SR, Lee KR. Vancomycin Dosing Practices, Trough Concentrations, and Predicted Area Under the Curve in Children With Suspected Invasive Staphylococcal Infections. J Pediatric Infect Dis Soc 2013; 2:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel K, Crumby AS, Maples HD. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? Paediatr Drugs 2015; 17:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children. Lancet 2020; 396:786.
          </a>
         </li>
         <li class="breakAll">
          Mani CS. Acute pneumonia and its complications. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.238.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffer FA, Bloom DA, Colin AA, Fishman SJ. Lung abscess versus necrotizing pneumonia: implications for interventional therapy. Pediatr Radiol 1999; 29:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerem E, Bar Ziv Y, Rudenski B, et al. Bacteremic necrotizing pneumococcal pneumonia in children. Am J Respir Crit Care Med 1994; 149:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy VP, Patamasucon P, Gaines T, Lucas MA. Necrotizing pneumococcal pneumonia in childhood. Pediatr Pulmonol 1999; 28:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan TQ, Seilheimer DK, Kaplan SL. Pediatric lung abscess: clinical management and outcome. Pediatr Infect Dis J 1995; 14:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Ginsberg RJ, Todd TR. Tube drainage of lung abscesses. Ann Thorac Surg 1987; 44:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuhdi MK, Spear RM, Worthen HM, Peterson BM. Percutaneous catheter drainage of tension pneumatocele, secondarily infected pneumatocele, and lung abscess in children. Crit Care Med 1996; 24:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emanuel B, Shulman ST. Lung abscess in infants and children. Clin Pediatr (Phila) 1995; 34:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunyoshi V, Cataneo DC, Cataneo AJ. Complicated pneumonias with empyema and/or pneumatocele in children. Pediatr Surg Int 2006; 22:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceruti E, Contreras J, Neira M. Staphylococcal pneumonia in childhood. Long-term follow-up including pulmonary function studies. Am J Dis Child 1971; 122:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soto M, Demis T, Landau LI. Pulmonary function following staphylococcal pneumonia in children. Aust Paediatr J 1983; 19:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amitai I, Mogle P, Godfrey S, Aviad I. Pneumatocele in infants and children. Report of 12 cases. Clin Pediatr (Phila) 1983; 22:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook KM, Gillon J, Grisso AG, et al. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study. J Pediatric Infect Dis Soc 2019; 8:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lassi ZS, Imdad A, Bhutta ZA. Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Cochrane Database Syst Rev 2017; 10:CD008032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl 3:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Same RG, Amoah J, Hsu AJ, et al. The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. J Pediatric Infect Dis Soc 2021; 10:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med 2004; 98:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahti E, Peltola V, Waris M, et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax 2009; 64:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esposito S. Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy. Chemotherapy 2001; 47 Suppl 1:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCrossan P, McNaughten B, Shields M, Thompson A. Is follow up chest X-ray required in children with round pneumonia? Arch Dis Child 2017; 102:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griscom NT. Pneumonia in children and some of its variants. Radiology 1988; 167:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly LF. Maximizing the usefulness of imaging in children with community-acquired pneumonia. AJR Am J Roentgenol 1999; 172:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YW, Donnelly LF. Round pneumonia: imaging findings in a large series of children. Pediatr Radiol 2007; 37:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLennan MK. Radiology rounds. Round pneumonia. Can Fam Physician 1998; 44:751, 757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggli KD, Newman B. Nodules, masses, and pseudomasses in the pediatric lung. Radiol Clin North Am 1993; 31:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose RW, Ward BH. Spherical pneumonias in children simulating pulmonary and mediastinal masses. Radiology 1973; 106:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman LK, Wald ER, Nair P, Papiez J. Roentgenographic follow-up of acute pneumonia in children. Pediatrics 1979; 63:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005; 40:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson NA, Hollman AS, Paton JY. Value of radiological follow up of childhood pneumonia. BMJ 1993; 307:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heaton P, Arthur K. The utility of chest radiography in the follow-up of pneumonia. N Z Med J 1998; 111:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wacogne I, Negrine RJ. Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Arch Dis Child 2003; 88:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surén P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008; 97:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruckheimer E, Dolberg S, Shlesinger Y, et al. Primary lung abscess in infancy. Pediatr Pulmonol 1995; 19:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neuman MI, Hall M, Gay JC, et al. Readmissions among children previously hospitalized with pneumonia. Pediatrics 2014; 134:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark CE, Coote JM, Silver DA, Halpin DM. Asthma after childhood pneumonia: six year follow up study. BMJ 2000; 320:1514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastham KM, Hammal DM, Parker L, Spencer DA. A follow-up study of children hospitalised with community-acquired pneumonia. Arch Dis Child 2008; 93:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Yang S, Cao Q, et al. Pneumonia Mortality in Children Aged &lt;5 Years in 56 Countries: A Retrospective Analysis of Trends from 1960 to 2012. Clin Infect Dis 2017; 65:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501.
          </a>
         </li>
         <li class="breakAll">
          Olarte L, Barson WJ, Barson RM, et al. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era (abstract). 9th World Congress of The World Society for Pediatric Infectious Diseases (WSPID), Rio de Janeiro, Brazil. November 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6054 Version 67.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903691" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719321" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Community acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11832532" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16990097" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16990097" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16990097" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24615334" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10585993" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1500133" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Frequency and significance of electrolyte abnormalities in pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1283678" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hyponatraemia and the inappropriate ADH syndrome in pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3924221" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chest physiotherapy in primary pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/361656" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chest physical therapy for children with pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3926095" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Chest physiotherapy in primary pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18276723" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Chest physical therapy for children hospitalised with acute pneumonia: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23000693" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chest physiotherapy in paediatric patients hospitalised with community-acquired pneumonia: a randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30601584" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Chest physiotherapy for pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23401275" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22588852" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Efficacy of methylprednisolone in children with severe community acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29236286" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Corticosteroids for pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26407353" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adjunct Systemic Corticosteroid Therapy in Children With Community-Acquired Pneumonia in the Outpatient Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15024437" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6391389" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439797" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978922" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Differentiation of bacterial and viral pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25714161" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Community-acquired pneumonia requiring hospitalization among U.S. children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15678226" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10783017" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Etiology of community-acquired pneumonia in 254 hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8444202" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Aetiology of community-acquired pneumonia in children treated in hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9849979" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Etiology of childhood pneumonia: serologic results of a prospective, population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8072825" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11040149" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Community acquired pneumonia--a prospective UK study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182396" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182396" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24324001" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparative effectiveness of empiric antibiotics for community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26341383" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9470026" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476773" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Failure of treatment of pneumonia associated with highly resistant pneumococci in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476773" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Failure of treatment of pneumonia associated with highly resistant pneumococci in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28403050" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27093162" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27078119" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29084336" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effectiveness ofβ-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30510032" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Getting Over Our Inpatient Oral Antibiotic Aversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17567657" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174874" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22209916" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11882730" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11332663" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891519" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Old and new antibiotics for pediatric pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19106348" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20888013" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21324473" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Vancomycin nephrotoxicity may be overstated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23471688" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nephrotoxicity in patients with vancomycin trough concentrations of 15-20μg/ml in a pediatric intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23652479" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619480" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Vancomycin Dosing Practices, Trough Concentrations, and Predicted Area Under the Curve in Children With Suspected Invasive Staphylococcal Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25644329" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32919518" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Complicated pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32919518" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Complicated pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9933325" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lung abscess versus necrotizing pneumonia: implications for interventional therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8111589" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Bacteremic necrotizing pneumococcal pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10495339" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Necrotizing pneumococcal pneumonia in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7715991" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pediatric lung abscess: clinical management and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3662682" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Tube drainage of lung abscesses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8605809" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Percutaneous catheter drainage of tension pneumatocele, secondarily infected pneumatocele, and lung abscess in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009257" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pneumonia in hospitalized children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7720324" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Lung abscess in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16362309" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Complicated pneumonias with empyema and/or pneumatocele in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5129527" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Staphylococcal pneumonia in childhood. Long-term follow-up including pulmonary function studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6651664" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pulmonary function following staphylococcal pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6839622" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pneumatocele in infants and children. Report of 12 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973124" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590376" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020436" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7518766" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Parenteral-oral switch in the management of paediatric pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32525203" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15191032" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Non-infectious and unusual infectious mimics of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11597287" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Macrolide resistance among invasive Streptococcus pneumoniae isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19052043" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Induced sputum in the diagnosis of childhood community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8059798" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096187" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11927745" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29021188" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Is follow up chest X-ray required in children with round pneumonia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9068582" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A practical guide for the diagnosis and treatment of pediatric pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3357939" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pneumonia in children and some of its variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9930814" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Maximizing the usefulness of imaging in children with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17952428" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Round pneumonia: imaging findings in a large series of children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9585845" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Radiology rounds. Round pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497596" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Nodules, masses, and pseudomasses in the pediatric lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4682716" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Spherical pneumonias in children simulating pulmonary and mediastinal masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/440799" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Roentgenographic follow-up of acute pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16010671" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Radiographic follow-up of pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8251812" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Value of radiological follow up of childhood pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9765629" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The utility of chest radiography in the follow-up of pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12716727" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18076723" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Radiographic follow-up of community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7792123" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Primary lung abscess in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24958590" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Readmissions among children previously hospitalized with pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10834897" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Asthma after childhood pneumonia: six year follow up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381341" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A follow-up study of children hospitalised with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020363" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Pneumonia Mortality in Children Aged&lt;5 Years in 56 Countries: A Retrospective Analysis of Trends from 1960 to 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10667183" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22327872" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22327872" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15794968" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
